Literature DB >> 11349057

Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice.

G I Sanchez1, M Sedegah, W O Rogers, T R Jones, J Sacci, A Witney, D J Carucci, N Kumar, S L Hoffman.   

Abstract

The gene encoding the 60-kDa heat shock protein of Plasmodium yoelii (PyHsp60) was cloned into the VR1012 and VR1020 mammalian expression vectors. Groups of 10 BALB/c mice were immunized intramuscularly at 0, 3, and 9 weeks with 100 microg of PyHsp60 DNA vaccine alone or in combination with 30 microg of pmurGMCSF. Sera from immunized mice but not from vector control groups recognized P. yoelii sporozoites, liver stages, and infected erythrocytes in an indirect fluorescent antibody test. Two weeks after the last immunization, mice were challenged with 50 P. yoelii sporozoites. In one experiment the vaccine pPyHsp60-VR1012 used in combination with pmurGMCSF gave 40% protection (Fisher's exact test; P = 0.03, vaccinated versus control groups). In a second experiment this vaccine did not protect any of the immunized mice but induced a delay in the onset of parasitemia. In neither experiment was there any evidence of a protective effect against the asexual erythrocytic stage of the life cycle. In a third experiment mice were primed with PyHsp60 DNA, were boosted 2 weeks later with 2 x 10(3) irradiated P. yoelii sporozoites, and were challenged several weeks later. The presence of PyHsp60 in the immunization regimen did not lead to reduced blood-stage infection or development of parasites in hepatocytes. PyHsp60 DNA vaccines were immunogenic in BALB/c mice but did not consistently, completely protect against sporozoite challenge. The observation that in some of the PyHsp60 DNA vaccine-immunized mice there was protection against infection or a delay in the onset of parasitemia after sporozoite challenge deserves further evaluation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349057      PMCID: PMC98419          DOI: 10.1128/IAI.69.6.3897-3905.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.

Authors:  M Sedegah; W Weiss; J B Sacci; Y Charoenvit; R Hedstrom; K Gowda; V F Majam; J Tine; S Kumar; P Hobart; S L Hoffman
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

2.  Murine gamma delta T lymphocytes elicited during Plasmodium yoelii infection respond to Plasmodium heat shock proteins.

Authors:  J Kopacz; N Kumar
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  DNA immunization confers systemic, but not mucosal, protection against enteroinvasive bacteria.

Authors:  A Noll; N Bücheler; E Bohn; R Schirmbeck; J Reimann; I B Autenrieth
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

4.  Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes.

Authors:  N D Pacheco; C P Strome; F Mitchell; M P Bawden; R L Beaudoin
Journal:  J Parasitol       Date:  1979-06       Impact factor: 1.276

5.  Plasmodium yoelii: cloning and characterization of the gene encoding for the mitochondrial heat shock protein 60.

Authors:  G I Sanchez; D J Carucci; J Sacci; J H Resau; W O Rogers; N Kumar; S L Hoffman
Journal:  Exp Parasitol       Date:  1999-12       Impact factor: 2.011

6.  Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule.

Authors:  L S Anthony; H Wu; H Sweet; C Turnnir; L J Boux; L A Mizzen
Journal:  Vaccine       Date:  1999-01-28       Impact factor: 3.641

7.  Genetic control of immunity to Plasmodium yoelii sporozoites.

Authors:  W R Weiss; M F Good; M R Hollingdale; L H Miller; J A Berzofsky
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

Review 8.  Role of heat shock proteins in protection from and pathogenesis of infectious diseases.

Authors:  U Zügel; S H Kaufmann
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites.

Authors:  Y Charoenvit; S Mellouk; C Cole; R Bechara; M F Leef; M Sedegah; L F Yuan; F A Robey; R L Beaudoin; S L Hoffman
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

10.  Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens.

Authors:  Y Charoenvit; M F Leef; L F Yuan; M Sedegah; R L Beaudoin
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

View more
  6 in total

Review 1.  Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines.

Authors:  Godfree Mlambo; Nirbhay Kumar
Journal:  Eukaryot Cell       Date:  2008-09-19

2.  Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide.

Authors:  M G Hartley; M Green; G Choules; D Rogers; D G C Rees; S Newstead; A Sjostedt; R W Titball
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

3.  Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

Authors:  Joshua Arrington; Ralph P Braun; Lichun Dong; Deborah H Fuller; Michael D Macklin; Scott W Umlauf; Sarah J Wagner; Mary S Wu; Lendon G Payne; Joel R Haynes
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines.

Authors:  Cristina Fernandez-Arias; Clemente F Arias; Min Zhang; Miguel A Herrero; Francisco J Acosta; Moriya Tsuji
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

5.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

6.  The hookworm Ancylostoma ceylanicum intestinal transcriptome provides a platform for selecting drug and vaccine candidates.

Authors:  Junfei Wei; Ashish Damania; Xin Gao; Zhuyun Liu; Rojelio Mejia; Makedonka Mitreva; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan
Journal:  Parasit Vectors       Date:  2016-09-27       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.